ID   201T
AC   CVCL_X481
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_X481
DR   Cell_Model_Passport; SIDM00055
DR   Cosmic; 910550
DR   Cosmic-CLP; 1287381
DR   DepMap; ACH-002089
DR   EGA; EGAS00001000978
DR   GDSC; 1287381
DR   GEO; GSM827492
DR   GEO; GSM1669564
DR   PharmacoDB; 201T_7_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_X481
DR   Wikidata; Q54583071
RX   PubMed=9816093;
RX   PubMed=9816140;
RX   PubMed=10545285;
RX   PubMed=15735034;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA.
CC   Population: African American.
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Ala (c.721T>G); ClinVar=VCV000376665; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=88.81%; Native American=0%; East Asian, North=2.58%; East Asian, South=0%; South Asian=0%; European, North=3.06%; European, South=5.55% (PubMed=30894373).
CC   Miscellaneous: Age of donor from personal communication of Siegfried J.M.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 7,13
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 9,10
ST   TH01: 7
ST   TPOX: 6,8
ST   vWA: 15
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 05-10-23; Version: 21
//
RX   PubMed=9816093;
RA   Kasprzyk P.G., Sullivan T.L., Hunt J.D., Gubish C.T., Scoppa C.A.,
RA   Oelkuct M., Bird R.E., Fischer P.H., Siegfried J.M., King C.R.;
RT   "Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell
RT   lines in the absence of erbB-2 gene amplification.";
RL   Clin. Cancer Res. 2:75-80(1996).
//
RX   PubMed=9816140;
RA   Skrepnik N., Araya J.C., Qian Z., Xu H.-B., Hamide J., Mera R.,
RA   Hunt J.D.;
RT   "Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on
RT   human non-small cell lung carcinoma grown orthotopically in athymic
RT   nude mice.";
RL   Clin. Cancer Res. 2:1851-1857(1996).
//
RX   PubMed=10545285; DOI=10.1006/pupt.1999.0210;
RA   Siegfried J.M., Krishnamachary N., Gaither Davis A., Gubish C.,
RA   Hunt J.D., Shriver S.P.;
RT   "Evidence for autocrine actions of neuromedin B and gastrin-releasing
RT   peptide in non-small cell lung cancer.";
RL   Pulm. Pharmacol. Ther. 12:291-302(1999).
//
RX   PubMed=15735034; DOI=10.1158/0008-5472.CAN-04-1872;
RA   Stabile L.P., Lyker J.S., Gubish C.T., Zhang W.-P., Grandis J.R.,
RA   Siegfried J.M.;
RT   "Combined targeting of the estrogen receptor and the epidermal growth
RT   factor receptor in non-small cell lung cancer shows enhanced
RT   antiproliferative effects.";
RL   Cancer Res. 65:1459-1470(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//